MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why NNNN Stock dropped -3.12% Today — RQD Quant Desk Flash
$3.72 -3.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.69
Anbio Biotechnology (Class A) (NNNN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $535.3M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.69 (-0.75%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-5.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NNNN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY NNNN SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+14/20 pts (31% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 29.4 (OVERSOLD (<32))
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$4.66-32.8% Next Q
53
Q2 (-2Q)Grade C-$3.13+21.7% Next Q
50
Q3 (-1Q)Grade D$3.81-2.4% Next Q
48
CurrentGrade D$3.72-6.3% Hist 90D α
45
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NNNN Turnaround Squeeze
While NNNN currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.47) and Max Pain ($3.91) forces dealer call-delta covering toward $46.97.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NNNN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NNNN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NNNN Stock dropped -3.12% Today — RQD Quant Desk Flash
Anbio Biotechnology (Class A) (NNNN) dropped -3.12% to $3.72, trading at 2% of its 52-week range ($3.09 – $44.73). Stretched risk/reward at 84x P/E (17% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($3.09 – $44.73) with RSI-14 at 29.4 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.72 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 87.2% gross margin and $0 annual free cash flow.
Live NNNN Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NNNN)
- ✓Walkthrough of NNNN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NNNN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -86.95%🛡️ HOLDING TREND SUPPORT
2026-10-30O $3.75H $3.75L $3.33C $3.72VOL 39.0K
RES: $7.62SUP: $2.07SMA50: $5.47SMA200: $17.33
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NNNN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
48.0%/yr Implied 5Y Growth
vs. +5.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NNNN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NNNN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NNNN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NNNN)
Health Care Rank #479 of 1016
⚔️ TKNO vs NNNN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NNNN vs. TKNO, MYGN, ACHV, QDEL)
Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Anbio Biotechnology (Class A) (NNNN) ranks #479 by composite RQD confidence (45/100, grade D) and #436 by equity capitalization ($535.3M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. NNNN currently leads its immediate peer cohort in composite quantitative strength at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NNNN
ACTIVE
Anbio Biotechnology (Class A) | D | 45/100 | 83.6x | 87.2% | 17.0% | -3.12% | $535.3M | Benchmark Subject |
| TKNO Alpha Teknova Inc. | D | 44/100 | — | 33.2% | -21.3% | +2.93% | $499.2M | /tkno-vs-nnnn → |
| MYGN Myriad Genetics Inc. | D- | 39/100 | — | 69.9% | -35.0% | +0.60% | $638.0M | /mygn-vs-nnnn → |
| ACHV Achieve Life Sciences Inc. | D | 44/100 | — | — | -35.0% | +4.96% | $739.9M | /achv-vs-nnnn → |
| QDEL QuidelOrtho Corporation | E | 30/100 | — | — | -35.0% | -1.78% | $943.6M | /qdel-vs-nnnn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001982708In its most recent audited fiscal period (FY2025, filed 2025-12-31), Anbio Biotechnology (Class A) (NNNN) reported GAAP revenue of $8.6M (+5.6% vs. FY2024 revenue of $8.2M , and +28.8% cumulative change since FY2023) , GAAP net income of $6.4M, operating cash flow of -$6.7M, and free cash flow of -$6.7M (-423.9% YoY). On the balance sheet, NNNN closed FY2025 with $30.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $8.6M | $6.4M | -$6.7M | -$6.7M | $30.2M | — |
| FY2024 (FY) | 2024-12-31 | $8.2M | $2.4M | $2.1M | $2.1M | $18.9M | — |
| FY2023 (FY) | 2023-12-31 | $6.7M | $2.3M | $898.4K | $898.4K | — | — |
3. NNNN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NNNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Anbio Biotechnology (Class A) (NASDAQ: NNNN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $3.72 (-3.12% 1D, market cap $535.3M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NNNN ranks #479 in composite RQD confidence.
How does NNNN compare to TKNO and MYGN in the Health Care sector?
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NNNN carries a Roarable D (45/100 RQD), trailing P/E of 83.6x, gross margin of 87.2%, and ROIC of 17.0%. By comparison, TKNO (Alpha Teknova Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -21.3%, cap $499.2M) and MYGN (Myriad Genetics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $638.0M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NNNN?
Per NNNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001982708), Anbio Biotechnology (Class A) generated $8.6M in revenue (+5.6% YoY), $6.4M in net income, and -$6.7M in free cash flow against $30.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NNNN trading relative to its 50-day, 200-day, and 52-week technical levels?
NNNN last traded at $3.72 (-3.12% on volume of 41,343 shares), positioning the stock -31.99% below its 50-day simple moving average ($5.47) and -78.53% below its 200-day simple moving average ($17.33). Across its 52-week range of $3.09 to $44.73, NNNN sits at the 1.5% percentile with a 14-day RSI of 29.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.25 to $4.19).
NNNN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NNNN stock moving today?
Why NNNN Stock dropped -3.12% Today — RQD Quant Desk Flash. Stretched risk/reward at 84x P/E (17% return on capital) under elevated 10-year interest-rate pressure.